Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin… Read more
Gan & Lee Pharmaceuticals Co Ltd (603087) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.023x
Based on the latest financial reports, Gan & Lee Pharmaceuticals Co Ltd (603087) has a cash flow conversion efficiency ratio of 0.023x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥257.27 Million) by net assets (CN¥11.28 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Gan & Lee Pharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Gan & Lee Pharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Gan & Lee Pharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gan & Lee Pharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rubis SCA
PA:RUI
|
0.102x |
|
FDJ United
LSE:0A8B
|
N/A |
|
Vodacom Group Ltd PK
PINK:VDMCY
|
0.177x |
|
China International Marine Containers (Group) Co. Ltd
F:OCM
|
0.009x |
|
Cembra Money Bank AG
PINK:CMBNF
|
0.116x |
|
Galp Energa
PINK:GLPEY
|
0.146x |
|
Konecranes ABP
LSE:0MET
|
0.076x |
|
SHREE CEMENT LIMITED
NSE:SHREECEM
|
0.219x |
Annual Cash Flow Conversion Efficiency for Gan & Lee Pharmaceuticals Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Gan & Lee Pharmaceuticals Co Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥11.05 Billion | CN¥537.31 Million | 0.049x | +22.09% |
| 2023-12-31 | CN¥10.74 Billion | CN¥427.69 Million | 0.040x | +28.63% |
| 2022-12-31 | CN¥9.59 Billion | CN¥296.68 Million | 0.031x | -70.81% |
| 2021-12-31 | CN¥10.17 Billion | CN¥1.08 Billion | 0.106x | -23.64% |
| 2020-12-31 | CN¥8.94 Billion | CN¥1.24 Billion | 0.139x | -34.16% |
| 2019-12-31 | CN¥5.47 Billion | CN¥1.15 Billion | 0.211x | +115.48% |
| 2018-12-31 | CN¥4.27 Billion | CN¥418.04 Million | 0.098x | -65.62% |
| 2017-12-31 | CN¥3.34 Billion | CN¥949.60 Million | 0.285x | -16.55% |
| 2016-12-31 | CN¥2.26 Billion | CN¥769.63 Million | 0.341x | +13.29% |
| 2015-12-31 | CN¥1.49 Billion | CN¥447.42 Million | 0.301x | +2.44% |
| 2014-12-31 | CN¥1.04 Billion | CN¥305.22 Million | 0.294x | +5.28% |
| 2013-12-31 | CN¥733.22 Million | CN¥204.73 Million | 0.279x | -- |